Additionally, our model demonstrated lower predictive power for tumours on the trunk (model 3: AUC 0.929), suggesting that for larger lesions in this region, MDM2 amplification analysis should still be performed as standard practice. The gene discussed is MDM2; the disease is neoplasm.